Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
J Hepatol
; 65(2): 280-8, 2016 08.
Article
in En
| MEDLINE
| ID: mdl-26952006
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Hepatol
Journal subject:
GASTROENTEROLOGIA
Year:
2016
Document type:
Article
Country of publication:
Países Bajos